Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Multiple Myeloma Clinical Trial Enrollment in the Black American Population

October 20th 2022

An expert discusses the stigmas behind clinical trials and the shockingly low rate of enrollment by Black Americans with multiple myeloma.

Spreading Multiple Myeloma Awareness in the Local Community

October 20th 2022

Dr Craig Cole explains why awareness about multiple myeloma needs to be raised in Black American communities by healthcare workers.

Dr. Paul on the Future of CAR T-Cell Therapy in Multiple Myeloma Treatment

October 18th 2022

Barry Paul, MD, discusses the emerging benefits of integrating CAR T-cell therapy into treatment paradigms for patients with relapsed/refractory multiple myeloma.

Treatments Branch Out in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

October 18th 2022

Peter Voorhees, MD, highlights important topics that his colleagues discussed at the meeting, including the important role of up-front autologous stem cell transplant and distinct adverse effects to be aware of when using different CAR T-cell therapies.

Dr. Atrash on the Evolution of BCMA-Directed Therapies in Multiple Myeloma

October 17th 2022

Shebli Atrash, MD, discusses the development and current use of BCMA-targeted antibody-drug conjugates and CAR T-cell therapies for the treatment of patients with multiple myeloma.

Proteosome Inhibitors Plus CD38 Antibodies Elicit Encouraging Responses in Multiple Myeloma

October 15th 2022

Peter Voorhees, MD, discusses key points from his presentation on proteasome inhibitors in multiple myeloma and positive data with the agents in the transplant-eligible and transplant-ineligible populations.

Improving Access to Specialty Care in Multiple Myeloma

October 14th 2022

Experts on multiple myeloma share comprehensive insight on how to build better access to specialty care for patients of racial and ethnic minority groups.

Overcoming Barriers to Early Diagnosis in Multiple Myeloma

October 14th 2022

Expert perspectives on how to improve the early detection of multiple myeloma within patients belonging to racial and ethnic minority groups.

Barriers in the Diagnosis of Multiple Myeloma for Patients

October 13th 2022

Craig Cole, MD, describes the barriers that can affect the diagnosis of multiple myeloma.

Examining the Roots of Health Disparities in Multiple Myeloma

October 13th 2022

Joseph Mikhael, MD, introduces the topic of disparities in multiple myeloma and the concept of multicultural health care.

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022

Dr Brentjens discussed targeting the “enigmatic” GPRC5D protein, safety results with MCARH109, and the appropriate sequencing for the agent.

Multiple Myeloma: Disparities in Access to Transplantation and Novel Therapy

October 7th 2022

Closing out their review of the barriers racial and ethnic minority groups encounter in receiving care, expert panelists address access to transplantation or novel therapy.

Multiple Myeloma: Disparities in Access to Specialized Care

October 7th 2022

Comprehensive discussion on access to specialized care and how racial and ethnic minority groups encounter barriers in this setting.

GPRC5D Antigen–Targeted CAR T-cell Therapy Induces Strong Response in Resistant Multiple Myeloma

October 3rd 2022

MCARH109, a CAR T-cell therapy targeting the “enigmatic” GPRC5D antigen, generated remissions in 70.6% of patients with relapsed/refractory multiple myeloma.

Belantamab Mafodotin Combination Elicits Encouraging ORRs in Relapsed/Refractory Multiple Myeloma

October 1st 2022

Belantamab mafodotin plus lenalidomide and dexamethasone showed durable responses in patients with relapsed/refractory multiple myeloma.

Multiple Myeloma: Disparities in Time to Diagnosis

September 30th 2022

Panelists address how racial and ethnic minority groups experience disparity in time to diagnosis within the multiple myeloma treatment pathway.

Societal Determinants of Health in Multiple Myeloma

September 30th 2022

Expert panelists shift their attention to how social determinants of multiple myeloma impact the treatment received by racial and ethnic minority groups.

Biological Determinants of Health in Multiple Myeloma

September 23rd 2022

Focused discussion on the biological determinants of multiple myeloma and how its prevalence is reflected in racial and ethnic minority groups.

Overview of Multiple Myeloma and Health Equity

September 23rd 2022

Joseph Mikhael, MD, spearheads an overview on the prevalence of multiple myeloma in racial and ethnic minority groups in the context of health equity.

FDA Panel Opposes Continued Approval of Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma

September 22nd 2022

In a 14 to 2 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the benefit-risk profile of melphalan flufenamide is not favorable for the approved indicated population of patients with relapsed/refractory multiple myeloma.